Cyclerion Therapeutics Inc (CYCN) - Total Assets
Based on the latest financial reports, Cyclerion Therapeutics Inc (CYCN) holds total assets worth $9.98 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CYCN book value for net asset value and shareholders' equity analysis.
Cyclerion Therapeutics Inc - Total Assets Trend (2016–2025)
This chart illustrates how Cyclerion Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Cyclerion Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Cyclerion Therapeutics Inc's total assets of $9.98 Million consist of 46.4% current assets and 53.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.5% |
| Accounts Receivable | $1.00 Million | 10.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Cyclerion Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Cyclerion Therapeutics Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cyclerion Therapeutics Inc's current assets represent 46.4% of total assets in 2025, an increase from 7.1% in 2016.
- Cash Position: Cash and equivalents constituted 32.5% of total assets in 2025, up from 0.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 10.0% of total assets.
Cyclerion Therapeutics Inc Competitors by Total Assets
Key competitors of Cyclerion Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Cyclerion Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.15 | 5.83 | 3.30 |
| Quick Ratio | 5.15 | 5.83 | 3.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.73 Million | $3.50 Million | $30.98 Million |
Cyclerion Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Cyclerion Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.58 |
| Latest Market Cap to Assets Ratio | 1.25 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | $9.98 Million |
| Market Capitalization | $12.51 Million USD |
Valuation Analysis
Above Book Valuation: The market values Cyclerion Therapeutics Inc's assets above their book value (1.25x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Cyclerion Therapeutics Inc's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Cyclerion Therapeutics Inc (2016–2025)
The table below shows the annual total assets of Cyclerion Therapeutics Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $9.98 Million | +4.28% |
| 2024-12-31 | $9.57 Million | -28.41% |
| 2023-12-31 | $13.37 Million | -26.02% |
| 2022-12-31 | $18.08 Million | -69.53% |
| 2021-12-31 | $59.33 Million | -48.58% |
| 2020-12-31 | $115.38 Million | -38.13% |
| 2019-12-31 | $186.48 Million | +2419.63% |
| 2018-12-31 | $7.40 Million | +35.30% |
| 2017-12-31 | $5.47 Million | +41.16% |
| 2016-12-31 | $3.88 Million | -- |
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a sy… Read more